National Distribution of Cancer Genetic Testing in the United States

Kimberly Childers, Melinda Maggard‐Gibbons, James Macinko, Christopher P. Childers

JAMA Oncology · 2018 · 88 citations · 4 references

DOIFull text

Open access

Concepts

Abstract

between crizotinib and chemotherapy among responders, owing to the higher objective response rate in the crizotinib arm, it would undermine the treatment benefit with respect to DOR. A caveat for our proposal is that mean DOR depends on a specific time window that can be preselected based on clinical consideration. Empirically one may choose the largest possible time window beyond which a small proportion of patients (eg, 2%) remain at risk for P/D. Like other procedures such as hazard ratio estimation, this time window constraint may not be avoidable without a parametric model for extrapolation. Lastly, it can be quite informative to exam-

References

4